ITOS – iteos therapeutics, inc. (US:NASDAQ)
Stock Stats
News
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT [Seeking Alpha]
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients [Yahoo! Finance]
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
iTeos to Participate in Upcoming Investor Conferences
Form 8-K iTeos Therapeutics, Inc. For: Sep 14
Form 4 iTeos Therapeutics, Inc. For: Aug 08 Filed by: Detheux Michel
Form 10-Q iTeos Therapeutics, Inc. For: Jun 30
Form 4 iTeos Therapeutics, Inc. For: Aug 01 Filed by: Feltquate David
Form 3 iTeos Therapeutics, Inc. For: Jul 31 Filed by: Feltquate David
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.